DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Est. Return
12.76%
1 Year Est. Return
+12.76%
AUM
$5.51B
AUM Growth
+$465M
(+9.2%)
Holding
168
Top Buys
| 1 | +$76.3M | |
| 2 | +$67.9M | |
| 3 | +$54.1M | |
| 4 |
Legend Biotech
LEGN
|
+$43.3M |
| 5 |
Centene
CNC
|
+$27.9M |
Top Sells
| 1 | +$67.3M | |
| 2 | +$59.1M | |
| 3 | +$40.4M | |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
+$32.1M |
| 5 |
InMode
INMD
|
+$28M |
Sector Composition
| 1 | Healthcare | 89.05% |
| 2 | Real Estate | 0.41% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$6.5B
| $1.37B | 24.91% |
17,991,024
|
|
||
2
Oscar Health
OSCR
$5.34B
| $250M | 4.53% |
11,649,591
-191,227
|
|
||
3
Viatris
VTRS
$11.8B
| $215M | 3.89% |
24,023,907
+32,313
|
|
||
4
Merus
MRUS
$7.18B
| $178M | 3.23% |
3,384,628
+210,700
|
|
||
|
5
Centene
CNC
$17.7B
| $173M | 3.14% |
3,185,370
+513,449
|
|
||
6
ARS Pharmaceuticals
SPRY
$1.05B
| $170M | 3.08% |
9,724,508
-790,149
|
|
||
7
Indivior
INDV
$3.1B
| $156M | 2.83% |
10,567,160
|
|
||
8
United Therapeutics
UTHR
$19.5B
| $155M | 2.82% |
540,626
+265,400
|
|
||
9
Neurocrine Biosciences
NBIX
$13.7B
| $147M | 2.66% |
1,167,802
-321,198
|
|
||
10
Revolution Medicines
RVMD
$9.42B
| $125M | 2.26% |
3,384,072
+66,740
|
|
||
11
Brookdale Senior Living
BKD
$2.08B
| $107M | 1.94% |
15,362,264
-250,000
|
|
||
|
12
Legend Biotech
LEGN
$6.02B
| $105M | 1.91% |
2,962,338
+1,218,783
|
|
||
13
Pfizer
PFE
$139B
| $104M | 1.89% |
4,306,264
+958,968
|
|
||
14
AdaptHealth
AHCO
$1.26B
| $93.4M | 1.7% |
9,904,895
+193,485
|
|
||
15
NewAmsterdam Pharma
NAMS
$4.2B
| $92.6M | 1.68% |
5,115,953
+1,011,996
|
|
||
16
IDEAYA Biosciences
IDYA
$2.48B
| $82.3M | 1.49% |
3,915,311
+647,760
|
|
||
17
Vera Therapeutics
VERA
$1.95B
| $78.9M | 1.43% |
3,348,117
+2,298,117
|
|
||
18
Insmed
INSM
$34.7B
| $70.5M | 1.28% |
700,700
+242,700
|
|
||
19
Merck
MRK
$210B
| $67.9M | 1.23% |
+857,724
|
|
||
20
Catalyst Pharmaceutical
CPRX
$2.56B
| $62.5M | 1.13% |
2,879,476
-542,673
|
|
||
21
Larimar Therapeutics
LRMR
$371M
| $61.4M | 1.11% |
21,231,974
|
|
||
22
Baxter International
BAX
$11.9B
| $58.2M | 1.06% |
1,923,100
|
|
||
23
Bio-Rad Laboratories Class A
BIO
$8.63B
| $54.6M | 0.99% |
226,070
|
|
||
24
Disc Medicine
IRON
$2.61B
| $48.7M | 0.88% |
919,403
+137,070
|
|
||
25
Alnylam Pharmaceuticals
ALNY
$63.7B
| $47.3M | 0.86% |
145,000
|
|